ALACHUA, FL--(Marketwire - February 19, 2008) - Oragenics, Inc. (AMEX: ONI), a biotechnology development company focused on infectious diseases, announced today that it has been selected to receive a $0.5 million grant to advance development of its unique small peptide antibiotic synthesis program using the company’s proprietary Differentially Protected Orthogonal Lanthionine Technology (DPOLT™). This two-year Phase II grant, awarded through the Small Business Innovation Research (SBIR) program of the National Science Foundation (NSF), will support studies focused on the synthesis and testing of our lead antibiotic, MU1140™.
